

EXHIBIT A

1 Brian G. Arnold (SBN 186007)
2 barnold@kirkland.com
3 KIRKLAND & ELLIS LLP
4 777 South Figueroa Street
5 Los Angeles, CA 90017
6 (213)680-8400 (o); (213)680-8500 (f)

7 Mark A. Pals, P.C. (pro hac vice)
8 mpals@kirkland.com
9 Marcus E. Sernel (pro hac vice)
10 msernel@kirkland.com
11 KIRKLAND & ELLIS LLP
12 200 East Randolph Drive
13 Chicago, IL 60601
14 (312)861-2000 (o); (312)861-2200 (f)

15 John W. Keker (SBN 49092)
16 jwk@kvn.com
17 KEKER & VAN NEST, LLP
18 710 Sansome Street
19 San Francisco, CA 94111
20 (415)391-5400 (o); (415)397-7188 (f)

21 Daralyn J. Durie (SBN 169825)
22 ddurie@durietangri.com
23 Mark Lemley (SBN 155830)
24 mlemley@durietangri.com
25 DURIE TANGRI LEMLEY ROBERTS & KENT LLP
26 332 Pine Street, Suite 200
27 San Francisco, CA 94104
28 (415)362-6666 (o); (415)236-6300 (f)

Attorneys for GENENTECH, INC.

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
WESTERN DIVISION

CENTOCOR, INC.,
Plaintiff,

v.

GENENTECH, INC. AND CITY OF
HOPE NATIONAL MEDICAL
CENTER,
Defendants.

Case No: CV08-03573

**GENENTECH, INC.'S INITIAL
DISCLOSURE PURSUANT TO
FED. R. CIV. P. 26(a)(1)**

JURY TRIAL DEMANDED

Defendant Genentech, Inc. ("Genentech") hereby makes the following Initial Disclosures pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure.

I. INITIAL DISCLOSURES

A. Names and Addresses of Individuals (Fed. R. Civ. P. 26(a)(1)(A)(i)).

Genentech identifies the following individuals/entities and, where known, addresses and telephone numbers of individuals/entities likely to have discoverable information that Genentech may use to support its counterclaims or defenses, based on information reasonably available to Genentech at this time.

1. Various past and current employees or affiliates of Genentech or City of Hope ("COH") including, without limitation, the following individuals:

<u>Name</u>	<u>Contact</u>	<u>Subject</u>
Schmuel Cabilly, Ph.D.	COH Counsel ¹	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Herbert L. Heyneker, Ph.D.	Genentech Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
William E. Holmes, Ph.D.	Genentech Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Arthur D. Riggs, Ph.D.	COH Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Ronald B. Wetzels, Ph.D.	Genentech Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
L. Jeanne Perry, Ph.D.	Genentech Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Michael W. Rey	Genentech Counsel	Invention of subject matter claimed

¹ Initial contact with a witness should be directed to counsel for COH or Genentech, as indicated. Counsel may or may not be authorized to accept service on a designated witness's behalf.

		in U.S. Patent Nos. 4,816,567 and 6,331,415
Michael B. Mumford	Genentech Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
John E. Shively, Ph.D.	COH Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Yvonne Bobadilla	COH Counsel	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Kate H. Murashige, Esq.	Morrison & Foerster, LLP 3811 Valley Centre Drive Suite 500 San Diego, CA 92130 T: (858) 720-5112	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415; preparation of U.S. Patent Application No. 06/483,457
Max Hensley, Esq.	Genentech Counsel	Prosecution of U.S. Patent Nos. 4,816,567 and 6,331,415
Wendy Lee, Esq.	Genentech Counsel	Prosecution of U.S. Patent Nos. 6,331,415, and 6,417,335.
Sharon Crane, Esq.	Bingham McCutchen LLP 2020 K Street, NW Washington, DC 20006 T: (202) 373-6000	Prosecution of U.S. Patent No. 6,331,415
R. Danny Huntington, Esq.	Bingham McCutchen LLP 2020 K Street, NW Washington, DC 20006 T: (202) 373-6000	Interference No. 102,572
Tim Schwartz, Esq.	Genentech Counsel	Licensing of U.S. Patent No. 6,331,415
Sue Desmond Hellman, MD	Genentech Counsel	Commercial success of products made pursuant to the teachings of U.S. Patent No. 6,331,415
John Orwin	Genentech Counsel	Commercial success of products

		made pursuant to the teachings of U.S. Patent No. 6,331,415
Henry Lowman, Ph.D	Genentech Counsel	Methods of creating products made pursuant to the teachings of U.S. Patent No. 6,331,415
Gregory S. Blank	Genentech Counsel	Invention of subject matter claimed in U.S. Patent No. 6,417,335.
Carol D. Basey	Genentech Counsel	Invention of subject matter claimed in U.S. Patent No. 6,417,335.

2. Other individuals or entities including, without limitation, the following entities:

Global Pharmaceutical Supply Group LLC	3 Gateway Center 16th Floor Westwing Pittsburgh, PA 15222	Manufacture and supply of ReoPro, Remicade, CNTO 1275, and CNTO 148.
Centocor Biologics LLC		Manufacture and supply of ReoPro, Remicade, CNTO 1275, and CNTO 148.
Centocor B.V.		Manufacture and supply of ReoPro, Remicade, CNTO 1275, and CNTO 148.
JOM Pharmaceuticals		Sales and distribution of ReoPro, Remicade, CNTO 1275, and CNTO 148.

B. Documents and Tangible Things (Fed. R. Civ. P. 26(a)(1)(A)(ii)).

Copies of the non-privileged documents in Genentech's possession, custody, or control that Genentech may use to support its counterclaims and defenses (unless solely for impeachment) will be produced to plaintiff Centocor. Such documents include, but are not limited to, documents relating to the inventions claimed in U.S. Patent Nos. 4,816,567, 6,331,415, and 6,417,335, documents relating to the prosecution of U.S. Patent Nos. 4,816,567, 6,331,415, and 6,417,335, documents relating to Interference No. 102,572, documents relating to the case captioned

1 *Genentech, Inc. v. Celltech Therapeutics, Ltd.*, Case No. C-98-3926 MMC (Section
 2 146 proceeding), and documents relating to license agreements for U.S. Patent Nos.
 3 4,816,567, 6,331,415, and 6,417,335. Genentech has already produced the
 4 prosecution histories of U.S. Patent Nos. 4,816,567, 6,331,415, and 6,417,335;
 5 certain documents relating to Interference No. 102,572; and certain documents
 6 relating to Reexamination Control Nos. 90/007,859 and 90/007,542. These
 7 documents are and will be disclosed subject to, and without waiver of, the
 8 protections from disclosure afforded by the attorney-client privilege and the work
 9 product doctrine. Genentech reserves the right to object to the production of any
 10 document based on privilege or any other proper ground. Genentech will produce
 11 confidential, non-privileged documents after the entry of an appropriate protective
 12 order.

13 Because discovery and investigation are continuing, Genentech anticipates
 14 that it may later become aware of, or appreciate the significance of, additional
 15 documents and things in the possession, custody, or control of Genentech. Without
 16 obligating itself to do so, Genentech reserves the right to supplement this initial
 17 disclosure pursuant to Rule 26(e) of the Federal Rules of Civil Procedure.

18 By providing the documents identified herein, Genentech does not waive the
 19 right to object to the production of other documents and things on the basis of any
 20 privilege or work-product protections, nor does Genentech concede that these
 21 documents necessarily are relevant to or admissible in this action. All evidentiary
 22 objections to the use of such documents are reserved.

23 **C. Damages (Fed. R. Civ. P. 26(a)(1)(A)(iii)).**

24 Genentech seeks damages to the extent permissible under the applicable laws.
 25 At this point, Genentech has not yet determined the full extent and/or nature of the
 26 injuries it has suffered and continues to suffer as a result of Centocor's infringement
 27 and imminent infringement. At a minimum, Genentech intends to seek a reasonable
 28 royalty for each infringing product made, sold, offered for sale, used, and/or

1 imported into the United States by, for, and/or on behalf of Centocor and/or as a
 2 result of Centocor's inducement of infringement and/or contributory infringement.
 3 Genentech also intends to seek treble damages and its attorneys fees due to
 4 Centocor's willful infringement of the '415 patent. Once Genentech has received
 5 information and documents from Centocor, Genentech will supplement its
 6 disclosure in accordance with Rule 26(e) of the Federal Rules of Civil Procedure or
 7 in the form of an interrogatory response if such an interrogatory is served, or
 8 through expert reports.

9 **D. Insurance Agreements (Fed. R. Civ. P. 26(a)(1)(A)(iv)).**

10 Genentech is presently unaware of any insurance agreements applicable to the
 11 claims asserted in the Complaint. Because discovery and investigation are
 12 continuing, Genentech reserves the right to supplement the initial disclosures
 13 pursuant to Rule 26(e) of the Federal Rules of Civil Procedure.

14
 15
 16
 17 Dated: February 23, 2009

18 KIRKLAND & ELLIS LLP

19 By: /s/ Marcus E. Sernel
 20 Marcus E. Sernel (pro hac vice)
 21 KIRKLAND & ELLIS LLP
 22 200 East Randolph Drive
 23 Chicago, IL 60601
 24 (312)861-2000 (o); (312)861-2200 (f)

25 *Attorney for Defendant Genentech, Inc.*

PROOF OF SERVICE

I, Shira J. Kapplin, am employed in the County of Cook, State of Illinois. I am over the age of 18 and not a party to the within action. My business address is 200 E. Randolph Street, Chicago, Illinois 60601.

On February 23, 2009, I served a true copy of the following document(s) described as:

**GENENTECH, INC.'S INITIAL DISCLOSURE PURSUANT
TO FED. R. CIV. P. 26(a)(1)**

on the interested parties in this action as follows:

☐ **By U.S. Mail:** By placing the document(s) listed above in a sealed envelope with postage thereon fully prepaid, in the United States mail at Los Angeles, California to the addressee(s) set forth below. I am "readily familiar" with the firm's practice of collection and processing correspondence for mailing. Under that practice, it would be deposited with the U.S. postal service on that same day with postage thereon fully prepaid at Los Angeles, California in the ordinary course of business. I am aware that on motion of the party served, service is presumed invalid if postal cancellation date or postage meter date is more than one day after date of deposit for mailing.

☒ **By Fedex:** By placing the document(s) listed above in a sealed overnight courier envelope addressed as set forth above and routing the envelope for pick up with Federal Express for overnight delivery.

Dianne B. Elderkin
Barbara L. Mullin
WOODCOCK WASHBURN LLP
2929 Arch St., 12th Floor
Philadelphia, PA 19104

Bruce G. Chapman
CONNOLLY BOVE LODGE & HUTZ LLP
333 S. Grand Ave., Suite 2300
Los Angeles, CA 90071

David I. Gindler
Joseph M. Lipner
IRELL & MANELLA LLP
1800 Avenue of the Stars, Suite 900
Los Angeles, California 90067-4276

☒ **By E-Mail:** I caused to have delivered such documents to the addressee as set forth below:

bchapman@cblh.com
kfraser@cblh.com

dgindler@irell.com
jlipner@irell.com

elderkin@woodcock.com
mullin@woodcock.com
maslowski@woodcock.com
akessel@woodcock.com
agoranin@woodcock.com
mpearson@woodcock.com

Executed February 23, 2009, at Chicago, Illinois.

Shira J. Kapplin
Print Name

/s/ Shira J. Kapplin
Signature

IRELL & MANELLA LLP
David I. Gindler (117824)
dgindler@irell.com
Joseph M. Lipner (155735)
jlipner@irell.com
1800 Avenue of the Stars, Suite 900
Los Angeles, California 90067-4276
Telephone: (310) 277-1010
Facsimile: (310) 203-7199

Attorneys for CITY OF HOPE
NATIONAL MEDICAL CENTER

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
WESTERN DIVISION

CENTOCOR, INC.,
Plaintiff,

v.

GENENTECH, INC. AND CITY OF
HOPE NATIONAL MEDICAL
CENTER,
Defendants.

Case No. CV 08-03573 MRP (CTx)
The Honorable Mariana R. Pfaelzer
**DEFENDANT CITY OF HOPE'S
INITIAL DISCLOSURES
PURSUANT TO FED. R. CIV. P.
26(a)(1)**
JURY TRIAL DEMANDED

Defendant City of Hope National Medical Center ("City of Hope") hereby
makes the following Initial Disclosures pursuant to Rule 26(a)(1) of the Federal
Rules of Civil Procedure.

I.

INITIAL DISCLOSURES

A. Names and Addresses of Individuals (Fed. R. Civ. P. 26(a)(1)(A)(i)).

City of Hope identifies the following individuals City of Hope currently
believes are likely to have discoverable information that it may use to support its
counterclaims or defenses, based on information reasonably available to City of
Hope at this time.

1. Past and current employees of Genentech, Inc. ("Genentech") or City of Hope including, without limitation, the following individuals:

Name	Contact	Subject
Shmuel Cabilly, Ph.D.	Irell & Manella LLP ¹ 1800 Avenue of the Stars, Suite 900 Los Angeles, CA 90067	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Herbert L. Heyneker, Ph.D.	Counsel for Genentech	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
William E. Holmes, Ph.D.	Counsel for Genentech	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Arthur D. Riggs, Ph.D.	Irell & Manella LLP 1800 Avenue of the Stars, Suite 900 Los Angeles, CA 90067	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Ronald B. Wetzel, Ph.D.	Counsel for Genentech	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
L. Jeanne Perry, Ph.D.	Counsel for Genentech	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Michael W. Rey	Counsel for Genentech	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Michael B. Mumford	Counsel for Genentech	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
John E. Shively, Ph.D.	Irell & Manella LLP 1800 Avenue of the Stars, Suite 900 Los Angeles, CA 90067	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415
Yvonne Bobadilla	Irell & Manella LLP 1800 Avenue of the Stars, Suite 900 Los Angeles, CA 90067	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415

¹ Initial contact with a witness should be directed to counsel for City of Hope or Genentech, as indicated. Counsel may or may not be authorized to accept service on a designated witness's behalf.

Name	Contact	Subject
Kate H. Murashige, Esq.	Morrison & Foerster, LLP 3811 Valley Centre Drive, Suite 500 San Diego, CA 92130 T: (858) 720-5112	Invention of subject matter claimed in U.S. Patent Nos. 4,816,567 and 6,331,415; preparation of U.S. Patent Application No. 06/483,457
Max Hensley, Esq.	Counsel for Genentech	Prosecution of U.S. Patent Nos. 4,816,567 and 6,331,415
Wendy Lee, Esq.	Counsel for Genentech	Prosecution of U.S. Patent Nos. 6,331,415, and 6,417,335.
Sharon Crane, Esq.	Bingham McCutchen LLP 2020 K Street, NW Washington, DC 20006 T: (202) 373-6000	Prosecution of U.S. Patent No. 6,331,415
R. Danny Huntington, Esq.	Bingham McCutchen LLP 2020 K Street, NW Washington, DC 20006 T: (202) 373-6000	Interference No. 102,572
Tim Schwartz, Esq.	Counsel for Genentech	Licensing of U.S. Patent No. 6,331,415
Sue Desmond Hellman, MD	Counsel for Genentech	Commercial success of products made pursuant to the teachings of U.S. Patent No. 6,331,415
John Orwin	Counsel for Genentech	Commercial success of products made pursuant to the teachings of U.S. Patent No. 6,331,415
Henry Lowman, Ph.D	Counsel for Genentech	Methods of creating products made pursuant to the teachings of U.S. Patent No. 6,331,415

2. Others individuals or entities including, without limitation, the following entities:

Name	Contact	Subject
Global Pharmaceutical Supply Group LLC	3 Gateway Center 16th Floor Westwing Pittsburgh, PA 15222	Manufacture and supply of ReoPro, Remicade, CNTO 1275, and CNTO 148.
Centocor Biologics LLC		Manufacture and supply of ReoPro, Remicade, CNTO 1275, and CNTO 148.
Centocor B.V.		Manufacture and supply of ReoPro, Remicade, CNTO 1275, and CNTO 148.

Name	Contact	Subject
JOM Pharmaceuticals		Sales and distribution of ReoPro, Remicade, CNTO 1275, and CNTO 148.

B. Documents and Tangible Things (Fed. R. Civ. P. 26(a)(1)(A)(ii)).

City of Hope will produce non-privileged documents in its possession, custody, or control that City of Hope may use to support its counterclaims and defenses (unless solely for impeachment) so long as those documents do not duplicate documents produced by Genentech. In addition, City of Hope expects it will rely on documents produced by Genentech. Such documents include, but are not limited to, documents relating to the inventions claimed in U.S. Patent Nos. 4,816,567 and 6,331,415, documents relating to the prosecution of U.S. Patent Nos. 4,816,567 and 6,331,415, documents relating to Interference No. 102,572, documents relating to the case captioned *Genentech, Inc. v. Celltech Therapeutics, Ltd.*, Case No. C-98-3926 MMC (Section 146 proceeding), and documents relating to license agreements for U.S. Patent Nos. 4,816,567 and 6,331,415. Genentech has already produced the prosecution histories of U.S. Patent Nos. 4,816,567 and 6,331,415; certain documents relating to Interference No. 102,572; and certain documents relating to Reexamination Control Nos. 90/007,859 and 90/007,542. These documents are and will be disclosed subject to, and without waiver of, the protections from disclosure afforded by the attorney-client privilege and the work product doctrine. City of Hope reserves the right to object to the production of any document based on privilege or any other proper ground. City of Hope too will produce confidential, non-privileged documents after the entry of an appropriate protective order.

Because discovery and investigation are continuing, City of Hope may produce additional documents. Without obligating itself to do so, City of Hope reserves the right to supplement this initial disclosure pursuant to Rule 26(e) of the Federal Rules of Civil Procedure.

1 By providing the documents identified herein, City of Hope does not waive
2 the right to object to the production of other documents and things on the basis of
3 any privilege or work-product protections, nor does City of Hope concede that these
4 documents necessarily are relevant to or admissible in this action. All evidentiary
5 objections to the use of such documents are reserved.

6 **C. Damages (Fed. R. Civ. P. 26(a)(1)(A)(iii)).**

7 City of Hope seeks damages to the extent permissible under the applicable
8 laws. At this point, City of Hope has not yet determined the full extent and/or
9 nature of the injuries it has suffered and continues to suffer as a result of Centocor's
10 infringement and imminent infringement. At a minimum, City of Hope intends to
11 seek a reasonable royalty for each infringing product made, sold, offered for sale,
12 used, and/or imported into the United States by, for, and/or on behalf of Centocor
13 and/or as a result of Centocor's inducement of infringement and/or contributory
14 infringement. City of Hope also intends to seek treble damages and its attorneys
15 fees due to Centocor's willful infringement of the '415 patent. Once City of Hope
16 has received information and documents from Centocor, City of Hope will
17 supplement its disclosure in accordance with Rule 26(e) of the Federal Rules of
18 Civil Procedure or in the form of an interrogatory response if such an interrogatory
19 is served, or through expert reports.

20 **D. Insurance Agreements (Fed. R. Civ. P. 26(a)(1)(A)(iv)).**

21 City of Hope is presently unaware of any insurance agreements applicable to
22 the claims asserted in the Complaint. Because discovery and investigation are
23 continuing, City of Hope reserves the right to supplement the initial disclosures
24 pursuant to Rule 26(e) of the Federal Rules of Civil Procedure.

25
26
27
28

1 Dated: February 23, 2009

Respectfully submitted,

2 IRELL & MANELLA LLP
3 David I. Gindler
4 Joseph M. Lipner

5
6 By: 

7 Joseph M. Lipner
8 Attorneys for CITY OF HOPE
9 NATIONAL MEDICAL CENTER
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

PROOF OF SERVICE

I am employed in the County of Los Angeles, State of California. I am over the age of 18 and not a party to the within action. My business address is 1800 Avenue of the Stars, Suite 900, Los Angeles, California 90067-4276.

On February 23, 2009, I served the foregoing document described as **DEFENDANT CITY OF HOPE'S INITIAL DISCLOSURES PURSUANT TO FED. R. CIV. P. 26(a)(1)** on each interested party, as stated on the attached service list.

☒ (BY OVERNIGHT DELIVERY SERVICE) I served the foregoing document by FedEx, an express service carrier which provides overnight delivery, as follows. I placed a true copy of the foregoing document in sealed envelopes or packages designated by the express service carrier, addressed, as stated on the attached service list, with fees for overnight delivery paid or provided for.

☒ (BOX DEPOSIT) I deposited such envelopes or packages in a box or other facility regularly maintained by the express service carrier.

☐ (CARRIER PICK-UP) I delivered such envelopes or packages to an authorized carrier or driver authorized by the express service carrier to receive documents.


☒ (BY ELECTRONIC MAIL) I caused the foregoing document to be served electronically by electronically mailing a true and correct copy through Irell & Manella LLP's electronic mail system to the e-mail address(es), as stated on the attached service list, and the transmission was reported as complete and no error was reported.

Executed on February 23, 2009, at Los Angeles, California.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Celia B. Silver

(Type or print name)



(Signature)

SERVICE LIST

Dianne B. Elderkin, Esq.
Barbara L. Mullin, Esq.
Steven D. Maslowski, Esq.
Amanda M. Kessel, Esq.
Aleksander J. Goranin, Esq.
Matthew A. Pearson, Esq.
WOODCOCK WASHBURN LLP
2929 Arch Street, 12th Floor
Philadelphia, Pennsylvania 19104-2891

Email: elderkin@woodcock.com
mullin@woodcock.com
maslowski@woodcock.com
akessel@woodcock.com
agoranin@woodcock.com
mpearson@woodcock.com

Brian G. Arnold, Esq.
KIRKLAND & ELLIS LLP
777 South Figueroa Street
Los Angeles, California 90017

Email: barnold@kirkland.com

John W. Keker, Esq.
KEKER & VAN NEST, LLP
710 Sansome Street
San Francisco, California 94111

Email: jwk@kvn.com

Bruce G. Chapman, Esq.
Keith D. Fraser, Esq.
CONNOLLY BOVE LODGE
& HUTZ LLP
333 South Grand Avenue, Suite 2300
Los Angeles, California 90071

Email: bchapman@cblh.com
kfraser@cblh.com

Mark A. Pals, P.C.
Marcus E. Sernel, Esq.
KIRKLAND & ELLIS LLP
200 East Randolph Drive
Chicago, Illinois 60601

Email: mpals@kirkland.com
msernel@kirkland.com

Daralyn J. Durie, Esq.
Mark Lemley, Esq.
DURIE TANGRI LEMLEY ROBERTS
& KENT LLP
332 Pine Street, Suite 200
San Francisco, California 94104

Email: ddurie@durietangri.com
mlemley@durietangri.com